Capital for Cures AG

The Short Version

Capital for Cures AG is a newly formed Swiss platform aiming to create a dedicated market for royalty-based financing in European biotech, a segment where traditional venture capital is often misaligned with the capital needs of asset-heavy, long-development-cycle companies [Capital for Cures site]. The company, founded in 2025 by physician and health economist Sebastian Gensior, seeks to connect private capital allocators, particularly family offices, with biotech and healthcare companies seeking non-dilutive funding tied to future intellectual property revenue streams [LinkedIn, 2025]. Its core proposition is not as a regulated fund but as an origination and infrastructure platform designed to source, structure, and facilitate these specialized transactions [Capital for Cures site].

Founder Sebastian Gensior brings a specific profile to this challenge, with a background as an MD specialized in clinical drug development and extensive experience in health economics and market access negotiations with global regulatory bodies [LinkedIn, 2026]. This domain expertise underpins the venture's credibility in navigating the complex intersection of science, finance, and regulation. The company appears to be in a foundational, pre-revenue stage, with no disclosed external funding rounds.

Over the next 12-18 months, the key indicators to monitor will be the announcement of the firm's first live transactions or partnerships, which would validate its ability to execute on its origination thesis, and any formal capital raise to fund platform development and deal sourcing operations. The absence of press coverage and specific customer names to date underscores the early, pre-validation nature of the venture. Data Accuracy: YELLOW -- Core company description and founder background are confirmed via primary sources.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed

The Company in Brief

Capital for Cures AG is a Swiss public limited company, or Aktiengesellschaft, formally incorporated in Zurich in 2025 [LinkedIn, January 2025]. The entity was established by Sebastian Gensior, who announced the launch on LinkedIn, framing it as a mission to bridge a funding gap for European biotech and healthcare companies [LinkedIn, January 2025]. The company's stated purpose is to operate as a pharmaceutical royalty origination platform, connecting private capital with assets in need of non-dilutive, structured financing [Capital for Cures AG].

The firm's early milestones are limited to its founding and initial positioning. A notable early activity was the hosting of a "Capital for Cures Summit London" in partnership with SS&C Intralinks, an event focused on rethinking biotech funding models [SS&C Intralinks]. The founder also opened a related event in Milan titled "Rewiring Biotech Funding," calling for a mindset shift in the industry [Intralinks]. Data Accuracy: YELLOW -- Company incorporation and mission confirmed via founder's LinkedIn and corporate site; event partnerships cited.

What They Have Built

The platform's core function is to connect two distinct groups, a process the company frames as building infrastructure for a specific type of financial transaction. Capital for Cures AG describes itself as a "Zurich-based pharmaceutical royalty origination platform" [Capital for Cures site]. Its public materials position it as a connector between biotech and healthcare companies seeking non-dilutive, royalty-based financing and private capital allocators, such as family offices, looking for exposure to these assets [LinkedIn, 2025]. The company explicitly states it is not a regulated investment manager, broker-dealer, or placement agent, a distinction that clarifies its role as an originator and facilitator rather than a principal or regulated intermediary [Capital for Cures site].

Available details on the mechanics of this connection are limited. The firm's focus is on royalty-based deals and intellectual property-backed financing, aiming to diversify capital sources for what it terms "breakthrough science" [Intralinks]. The operational model appears to rely on the founder's network and expertise in pharmaceutical deal-making rather than on a publicly detailed technology stack. Data Accuracy: YELLOW -- Product claims are sourced from the company's own site and social channels; the operational model and lack of a software product are inferred from the absence of contrary evidence in public materials.

Market Size and Demand

The thesis for a platform connecting private capital to biotech royalties rests on a persistent funding gap for European life sciences companies, a gap that has widened as traditional venture capital has become more selective.

The global pharmaceutical royalty and milestone finance market, which includes the type of non-dilutive funding Capital for Cures aims to facilitate, is a multi-billion dollar segment. For context, Royalty Pharma, one of the named competitors, reported total income of $2.4 billion in 2023 [Royalty Pharma, 2023]. The European biotech sector, which the company explicitly targets for improved capital access, raised approximately €5.3 billion in venture funding in 2023, a figure that represents a significant decline from prior years and underscores the capital-access challenge [BioCentury, 2024].

Metric	Value
European Biotech VC (2023)	5.3 €B
Global Pharma Royalty Finance (Analogous)	2.4 $B
Data Accuracy: YELLOW -- Market sizing relies on analogous data from public company reports and industry analyses.

Who Else Is Fighting for This

Capital for Cures AG enters a specialized niche, positioning itself as a pure-originator platform connecting capital to biotech assets, a model that sits between large-scale royalty aggregators and traditional venture capital.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Capital for Cures AG	Swiss-based platform for originating and connecting private capital to biotech/pharma royalty and IP-backed financing deals.	Pre-seed; no disclosed funding.	Focus on European biotech; positions as a non-regulated originator/infrastructure layer, not a fund.	[Capital for Cures site]; [LinkedIn, 2025]
Royalty Pharma	Publicly traded (RPRX) acquirer and funder of royalty interests in commercial-stage biopharmaceutical products.	Public company; $26B market cap.	Scale and capital to acquire large, mature royalty streams on commercialized drugs.	[Company Filings]
HealthCare Royalty Partners	Private investment firm providing non-dilutive capital to life sciences companies via royalties and credit.	Private firm; multiple funds totaling billions.	Long-standing track record with institutional LPs; deep sector expertise for structuring complex deals.	[Firm Website]
Oberland Capital Management	Healthcare-focused investment firm providing structured financing solutions, including royalties and credit.	Private firm; over $4B in assets under management.	Broad mandate across healthcare services, products, and life sciences with flexible capital solutions.	[Firm Website]
XOMA	Publicly traded (XOMA) biotech royalty aggregator and developer, acquiring rights to royalty streams on commercial assets.	Public company; ~$300M market cap.	Hybrid model of royalty acquisition and early-stage venture investment in drug discovery.	[Company Filings]

Data Accuracy: YELLOW -- Competitor profiles and the subject's positioning are confirmed by public sources and company statements.

Opportunity

The prize for Capital for Cures AG, if it executes, is a central position in the multi-billion dollar market for non-dilutive biotech financing, connecting a fragmented supply of private capital with a persistent demand for alternative funding structures in European life sciences.

Scenario	What happens	Catalyst	Why it's plausible
The European Royalty Aggregator	The platform becomes the primary source for family offices and private capital to access vetted, mid-size European biotech royalty streams.	A public announcement of the first successfully syndicated royalty deal, providing a reference transaction and proof of execution.	Founder Sebastian Gensior's deep network in European health economics and reimbursement provides direct access to both biotech executives and the financial decision-makers at family offices [LinkedIn, 2026].
The Regulatory & Policy Conduit	Capital for Cures evolves into a trusted intermediary that helps shape European policy on IP-backed financing, becoming indispensable for cross-border deals.	Hosting or co-authoring a white paper with a major financial infrastructure partner like Intralinks on standardizing royalty contracts in Europe.	The company has already demonstrated an ability to convene industry stakeholders through its summits in London and Milan, signaling a focus on thought leadership and ecosystem building [Intralinks].
Data Accuracy: YELLOW -- The opportunity thesis is built on cited market gaps and founder background.

Sources

1. [Capital for Cures site] Capital for Cures AG | https://capitalforcures.com
2. [LinkedIn, January 2025] Capital for Cures is now a company - and a mission | https://www.linkedin.com/posts/sgensior_capital-for-cures-is-now-a-company-and-activity-7330490606718246914-1TiP
3. [SS&C Intralinks] Capital for Cures Summit London | https://www.intralinks.com/events/capital-for-cures-summit-london
4. [Intralinks] Rewiring Biotech Funding: Takeaways From Capital for Cures, Milan | https://www.intralinks.com/resources/blog/rewiring-biotech-funding-takeaways-capital-cures-milan
5. [Prospeo] Capital for Cures AG Profile | https://www.moneyhouse.ch/en/company/capital-for-cures-ag-3632606671
6. [Royalty Pharma, 2023] Royalty Pharma Reports Fourth Quarter and Full Year 2023 Financial Results | https://www.royaltypharma.com/news-releases/news-release-details/royalty-pharma-reports-fourth-quarter-and-full-year-2023
7. [BioCentury, 2024] European biotech funding | https://www.biocentury.com/article/650230/european-biotech-funding-2023-in-review
8. [LinkedIn, 2025] Why I Started Capital for Cures | https://www.linkedin.com/posts/sgensior_why-i-started-capital-for-cures-turning-activity-7282648492131442689-0Vxw
9. [LinkedIn, 2026] Sebastian Gensior - Capital for Cures AG | https://www.linkedin.com/in/sgensior/
10. [Firm Website] HealthCare Royalty Partners | https://www.healthcareroyalty.com/
11. [Firm Website] Oberland Capital Management | https://oberlandcapital.com/
12. [Company Filings] XOMA Corporation | https://investors.xoma.com/financial-information/sec-filings